Higher Insulin Sensitivity Linked to 30% Lower Death Risk in Fatty Liver Disease
Large study of 6,847 patients shows better glucose disposal rates significantly reduce mortality risk in metabolic liver disease.
Summary
A major study of 6,847 people with metabolic dysfunction-associated steatotic liver disease (MASLD) found that better insulin sensitivity dramatically reduces death risk. Researchers used the estimated glucose disposal rate (eGDR) to measure insulin resistance and tracked participants for nearly 9 years. Those with the highest insulin sensitivity had 30% lower diabetes death risk, 10% lower cardiovascular death risk, and 6% lower overall death risk compared to those with the worst insulin resistance. This suggests that improving insulin sensitivity through diet, exercise, and medication could be a key strategy for extending lifespan in the growing population with fatty liver disease.
Detailed Summary
Insulin resistance drives both fatty liver disease and premature death, but this massive study quantifies exactly how much insulin sensitivity matters for survival. Researchers analyzed 6,847 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) from the National Health and Nutrition Examination Survey, tracking them for a median of 8.8 years to determine mortality outcomes.
The team used the estimated glucose disposal rate (eGDR) as a comprehensive measure of insulin sensitivity, incorporating waist circumference, blood pressure status, and hemoglobin A1c levels. Participants were divided into four groups based on their eGDR scores, with the lowest quartile having eGDR values below 3.99 and the highest above 7.92.
The results were striking: during follow-up, 1,345 participants (19.6%) died, including 443 cardiovascular deaths (6.5%) and 89 diabetes-related deaths (1.3%). After adjusting for age, demographics, and health conditions, each unit increase in eGDR was associated with a 6% reduction in all-cause mortality (HR=0.94, p<0.001), a 10% reduction in cardiovascular death (HR=0.90, p<0.001), and a dramatic 30% reduction in diabetes mortality (HR=0.70, p<0.001).
The predictive power varied by outcome type. While eGDR showed modest ability to predict overall and cardiovascular death (AUC=0.606 and 0.631 respectively), it performed much better for diabetes mortality (AUC=0.729), suggesting insulin resistance is particularly crucial for diabetes-related survival.
These findings highlight insulin sensitivity as a modifiable risk factor that could significantly extend lifespan in people with fatty liver disease. However, the study's observational design means it cannot prove causation, and the eGDR calculation may not capture all aspects of insulin resistance compared to gold-standard testing methods.
Key Findings
- Each 1-unit increase in eGDR associated with 30% lower diabetes mortality risk (HR=0.70, p<0.001)
- Higher insulin sensitivity linked to 10% lower cardiovascular death risk (HR=0.90, p<0.001)
- Overall mortality reduced by 6% per unit increase in eGDR (HR=0.94, p<0.001)
- During 8.8-year follow-up, 19.6% of 6,847 MASLD patients died (1,345 deaths total)
- eGDR showed strong predictive ability for diabetes mortality (AUC=0.729) vs modest for overall death (AUC=0.606)
- Patients in lowest insulin sensitivity quartile had eGDR <3.99, highest quartile had eGDR ≥7.92
- Results remained consistent across subgroups including age, sex, race, and comorbidity status
Methodology
Retrospective cohort study analyzing 6,847 adults with MASLD from NHANES 1999-2018, followed for median 8.8 years. eGDR calculated using formula incorporating waist circumference, hypertension status, and HbA1c. Mortality data from National Death Index with cause-specific classification by ICD codes. Statistical analysis included Cox proportional hazards models, restricted cubic splines, and ROC curves with extensive covariate adjustment.
Study Limitations
Observational design cannot establish causation between insulin sensitivity and mortality. eGDR is a surrogate measure that may not capture all aspects of insulin resistance compared to gold-standard hyperinsulinemic-euglycemic clamp testing. MASLD diagnosis relied on fatty liver index rather than imaging or biopsy. Potential residual confounding from unmeasured lifestyle or genetic factors.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.